Los puntos clave no están disponibles para este artículo en este momento.
In this cohort study, drug survival was comparable between adalimumab, infliximab, and ustekinumab but significantly lower for etanercept. There were no differences in drug survival among biologic-naive and nonnaive patients.
Ring et al. (Wed,) studied this question.